Provider Briefing: The Insulin Glargine Supply Disruption

If your patients are reporting difficulty filling Lantus (Insulin Glargine) prescriptions, this guide provides the clinical and logistical context you need to respond effectively. The current disruption isn't a straightforward product shortage — it's a market-wide realignment that's creating real access barriers for patients dependent on basal insulin.

This briefing covers the timeline, prescribing implications, current availability picture, cost and access considerations, and actionable tools you can deploy in your practice.

Timeline of the Insulin Glargine Disruption

Understanding how we got here is essential for anticipating what comes next:

• 2021: FDA approved Semglee (Insulin Glargine-yfgn, Viatris/Biocon) as the first interchangeable biosimilar to Lantus
• 2022-2024: Semglee gained significant market share; many insurance formularies switched to Semglee as preferred Insulin Glargine
• 2023: Sanofi announced a 78% list price reduction for Lantus, effective 2024, and capped out-of-pocket costs at $35/month for commercially insured patients
• Mid-2025: Semglee began experiencing supply constraints; ASHP reported ongoing availability issues
• August 2025: Regional shortages of Semglee and Insulin Glargine-yfgn intensified, particularly in the Pacific Northwest and Northeast
• December 31, 2025: Biocon formally discontinued Semglee vials and pens
• January-March 2026: Demand shifted to brand Lantus, Basaglar, Rezvoglar, and generic Insulin Glargine; insurance plans updating formularies in real-time

Prescribing Implications

The primary clinical concern for prescribers is continuity of care. Patients who were stable on Semglee are now navigating formulary changes, pharmacy switches, and in some cases, product substitutions they don't fully understand.

Key Considerations

• Interchangeability: Semglee was FDA-designated as interchangeable with Lantus, meaning pharmacists could substitute without prescriber intervention. Now that Semglee is discontinued, patients need explicit prescriptions for their replacement product.
• Dose equivalence: Lantus, Basaglar, Rezvoglar, and generic Insulin Glargine (U-100) are dose-equivalent — 1:1 unit conversion. However, switching to Toujeo (U-300) requires careful dose calculation, as it is not a 1:1 substitution.
• Prior authorization burden: Some plans now require PA for brand Lantus where Semglee was previously auto-approved. Consider pre-emptively documenting the clinical rationale for Insulin Glargine in patient charts to expedite PA requests.
• Patient confusion: Many patients don't understand the difference between brand Lantus, biosimilars, and generics. Clear communication about product equivalence is valuable during transitions.

Prescribing Strategy

To maximize your patients' chances of filling their prescriptions:

1. Write prescriptions for "Insulin Glargine" (generic name) with permission to substitute when possible, giving pharmacies flexibility
2. Include a backup product on the prescription or provide patients with an alternative prescription they can fill if their primary is unavailable
3. Consider Toujeo (U-300) for patients requiring higher basal doses — it may have better availability due to different supply channels
4. For patients with frequent hypoglycemia or dosing adherence challenges, Tresiba (Insulin Degludec) offers clinical advantages independent of the supply situation

Current Availability Picture

As of early 2026, the availability status by product:

• Lantus (Sanofi): Available — vials and SoloStar pens in production. Intermittent pharmacy-level stock-outs in high-demand areas.
• Basaglar (Eli Lilly): Available — KwikPen format. Generally good availability.
• Rezvoglar (Eli Lilly): Available — biosimilar to Lantus.
• Generic Insulin Glargine: Available — from Winthrop and other manufacturers. Supply varies regionally.
• Semglee (Biocon/Viatris): Discontinued as of December 31, 2025.
• Toujeo (Sanofi): Available — SoloStar and Max SoloStar pens.
• Tresiba (Novo Nordisk): Available — FlexTouch pens in U-100 and U-200.

Cost and Access Considerations

The financial landscape for Insulin Glargine has improved significantly, though navigating it still requires awareness:

• Sanofi Valyou Savings Program: $35/month for Lantus — available to insured and uninsured patients
• Sanofi Copay Savings Card: $0-$35 copay for commercially insured patients
• Medicare Part D: $35/month insulin copay cap under the Inflation Reduction Act
• Sanofi Patient Connection: Free Lantus for eligible uninsured patients meeting income requirements
• Generic Insulin Glargine: As low as $35-$75 with discount cards
• 340B programs: Covered entities can access Lantus at significantly reduced prices

For your patients facing cost barriers, our patient savings guide provides a comprehensive rundown, and our provider guide to helping patients save offers workflow tips for your practice.

Tools and Resources for Your Practice

Several tools can help your team manage the supply disruption:

Medfinder for Providers

Medfinder allows providers and care teams to check real-time pharmacy stock for Lantus and other Insulin Glargine products by location. It's a practical tool for helping patients find available stock before they leave your office.

ASHP Drug Shortage Database

The ASHP Drug Shortage Resource Center provides regularly updated shortage status for Insulin Glargine injection, including manufacturer-specific availability notes.

FDA Drug Shortage Database

The FDA's shortage list provides official shortage designations and resolved shortage notices.

Manufacturer Support Lines

• Sanofi: 1-800-633-1610 (patient assistance and product availability)
• Eli Lilly: 1-800-545-6962 (Basaglar/Rezvoglar support)
• Novo Nordisk: 1-800-727-6500 (Tresiba/NovoCare)

Looking Ahead

The Insulin Glargine market is expected to stabilize through 2026 as:

• Insurance formularies complete their post-Semglee updates
• Distribution networks adjust to new demand patterns
• Manufacturers scale production to meet shifted demand
• Patient awareness of alternatives increases

However, the broader trend of insulin market consolidation — fewer manufacturers, complex pricing structures, and formulary dependence — means supply disruptions will likely remain a recurring challenge. Building practice workflows that account for medication access issues is a sound long-term investment.

Final Thoughts

The current Insulin Glargine supply disruption requires prescribers to be proactive, not reactive. Documenting clinical necessity, writing flexible prescriptions, maintaining awareness of alternative products, and connecting patients with cost-reduction programs are all within your direct control.

For real-time stock checking and patient tools, visit Medfinder for Providers. For patient-facing resources you can share, see our guide to finding Lantus in stock and our patient shortage update.